Showing results 1 to 3 of 3
Title | Author(s) | Issue Date | Views | |
---|---|---|---|---|
A Phase IIIb open-label, single-arm study of afatinib in EGFR TKI-naïve patients with EGFRm+ NSCLC: An interim analysis. Proceeding/Conference:World Lung Cancer Conference, 2017 | 2017 | 109 | ||
2022 | ||||
2021 | 19 |